Form 4: Ovid Therapeutics Executive Exercises Warrants

Ovid Therapeutics Executive Chairman Jeremy Levin exercised Series A Warrants to acquire 47,333 shares of common stock at $1.40 per share.

Summary

• Jeremy M. Levin, Executive Chairman and Director of Ovid Therapeutics Inc., acquired 47,333 shares of common stock.
• The acquisition occurred on March 23, 2026, through the exercise of Series A Warrants.
• The exercise price for each share was $1.40.
• Following this transaction, Mr. Levin directly beneficially owns 3,735,048 shares of common stock.
• Additionally, 35,461 shares are indirectly beneficially owned through Divo Holdings, LLC, though Mr. Levin disclaims beneficial ownership of these shares.
• The Series A Warrants became immediately exercisable following stockholder approval on December 11, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The Executive Chairman's decision to exercise warrants and increase his direct ownership stake suggests confidence in Ovid Therapeutics' future performance, although it is a single transaction.

Positives

• The Executive Chairman's exercise of warrants indicates confidence in the company's future prospects and valuation at or above the exercise price of $1.40 per share.
• The direct acquisition of 47,333 shares increases the insider's direct stake in the company, aligning management interests with shareholders.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the transaction details and the warrant expiration date.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the exercise of warrants by an executive, are often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or has significant upside potential. This aligns the executive's financial interests more closely with those of public shareholders.

Corporate Governance

Related Party Transactions

• Jeremy Levin disclaims beneficial ownership of 35,461 shares held indirectly through Divo Holdings, LLC, where his spouse is the manager. This is a standard disclosure for related party indirect ownership.

Stakeholder Impact

• Shareholders may view the Executive Chairman's increased direct ownership as a positive indicator of management's belief in the company's value and future prospects.
• The transaction reinforces alignment between executive incentives and shareholder returns.

Next Steps

• The Series A Warrants are set to expire on April 17, 2026, indicating a deadline for any remaining warrant exercises.

Key Dates

Recommendation

The Executive Chairman's decision to exercise warrants at a specific price and increase his direct equity stake is a strong signal of confidence in the company's future value. This insider buying suggests that management believes the stock is a worthwhile investment at or above the exercise price, which seasoned investors often interpret as a positive indicator for potential appreciation.

Keywords

Ovid Therapeutics, OVID, Jeremy Levin, Insider Transaction, Warrant Exercise, Common Stock, SEC Form 4